ClinicalTrials.gg
TerminatedNCT00443040Updated Jan 6, 2012Results posted

Asimadoline for the Treatment of Post-Operative Ileus

A Phase 2 interventional study of Asimadoline and Placebo in Post-Operative Ileus, sponsored by Tioga Pharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-01-06.

Sponsored by Tioga Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
poor enrollment (31 of a planned 114 subjects were randomized and evaluable)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Ileus with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Ileus · United States.

Enrollment
41st of 53
35 · median 80
Started
2007
with 4 others
Phase 2
11 of 59
none open now
Registered
9th of 59
by date

Among the 59 studies in Ileus with a site in United States, this one is the 41st largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 2, and was the 9th registered.

Ileus

167 studies on the registry are indexed under Ileus; 23 are open to participants now.

Browse Ileus studies →

Open to participants now

4 of the 59 studies in Ileus with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Ileus studies recruiting now, 12 (63%) set no upper age limit and 4 (21%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Ileus with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of asimadoline in patients who have undergone a laparoscopic segmental colectomy and determine whether it reduces the time to recovery of bowel function compared to placebo.

Read the detailed description

This randomized, double-blind, placebo-controlled study was designed to evaluate the efficacy and tolerability of two dose levels of asimadoline on the duration of post-operative ileus in subjects undergoing laparoscopic or hand-assisted laparoscopic colon resections. Subjects meeting entry criteria were randomized in a 1:1:1 ratio to receive either asimadoline 1.0 mg, asimadoline 3.0 mg or a placebo. One hundred and fourteen subjects were planned, and in the event that a subject was converted from a laparoscopic surgery to an open surgery (laparotomy), that subject would be discontinued from the trial and followed for safety only. The protocol allowed subjects converted to open procedures to be replaced. The first dose was administered approximately 90 minutes pre-operatively, and subsequent dosing was b.i.d. for up to 10 post-operative doses. Subjects were dosed with study drug only while in the hospital. After discharge, they were followed for an additional 28 days. Total study duration for each patient was approximately 5 to 6 weeks.

03

Conditions studied

  • Post-Operative Ileus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18-80
  • Must be scheduled to undergo a laparoscopic/hand-assisted laparoscopic segmental colectomy
  • Must sign an ICF
  • Females of must have a negative pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Subjects with evidence of a biochemical or structural abnormality of the GI tract or other co-morbid illness that may impact the ability to interpret the safety and efficacy data
  • Pregnant or breastfeeding females
  • Use of drugs in previous 30 days
  • Refusal to discontinue prohibited concomitant medications
  • Chronic use of prescription narcotics over the previous 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Asimadoline 1.0 mg

    Asimadoline 1.0 mg b.i.d.

    Drug: Asimadoline

  • Active comparator
    Asimadoline 3.0 mg

    Asimadoline 3.0 mg b.i.d.

    Drug: Asimadoline

Interventions

  • Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.

    Also known as: EMD 61 753, EMR 63 320

  • DrugPlacebo

    Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.

06

What researchers measure

Primary outcomes

  1. Time to Return of Upper and Lower GI Function

    The time to first bowel movement or the time to tolerating solid food, whichever occurs later.

    Time frame: Daily for 38 days

Secondary outcomes

  1. Time to Tolerating Solid Food

    Time to tolerating solid food (toleration is defined as the absence of nausea or vomiting) within 4 hours of ingesting a meal

    Time frame: 4 hours of ingesting a meal

  2. Time to First Passage of Flatus

    Time frame: Daily for 38 days

  3. Time to First Bowel Movement

    Time frame: Daily for 38 days

  4. Time to Writing of Hospital Discharge Order

    Time frame: Daily for 38 days

  5. Nausea Score

    Time frame: Daily for 38 days

  6. Vomiting Score

    Time frame: Daily for 38 days

  7. Pain Score

    Time frame: Daily for 38 days

  8. Nasogastric Tube Re-insertion

    Proportion of subjects with nasogastric tube re-insertion

    Time frame: Daily for 38 days

  9. Post-operative Analgesic Use

    Time frame: Daily for 38 days

  10. Adverse Events

    Adverse events grouped by body system

    Time frame: Daily for 38 days

  11. Laboratory Values

    Changes in laboratory values.

    Time frame: Daily for 38 days

07

Results

Posted Jan 6, 2012
Limitations and caveats
Early termination leading to small numbers of subjects analyzed; no efficacy analysis was completed.

Participant flow

Participant flow — Overall Study
MilestoneAsimadoline 1.0 mgAsimadoline 3.0 mgPlacebo
Started141110
Completed10119
Not completed401
Withdrew: Withdrawal by subject100
Withdrew: Converted to an open laparotomy301

Outcome measures

SecondaryTime to Tolerating Solid Food

Time to tolerating solid food (toleration is defined as the absence of nausea or vomiting) within 4 hours of ingesting a meal

Time frame:
4 hours of ingesting a meal
Reported as:
Number · participants

Results for this outcome have not been posted.

SecondaryTime to First Passage of Flatus
Time frame:
Daily for 38 days
Reported as:
Number · participants

Results for this outcome have not been posted.

SecondaryTime to First Bowel Movement
Time frame:
Daily for 38 days
Reported as:
Number · participants

Results for this outcome have not been posted.

SecondaryTime to Writing of Hospital Discharge Order
Time frame:
Daily for 38 days
Reported as:
Number · participants

Results for this outcome have not been posted.

SecondaryNausea Score
Time frame:
Daily for 38 days

Results for this outcome have not been posted.

SecondaryVomiting Score
Time frame:
Daily for 38 days

Results for this outcome have not been posted.

SecondaryPain Score
Time frame:
Daily for 38 days

Results for this outcome have not been posted.

PrimaryTime to Return of Upper and Lower GI Function

The time to first bowel movement or the time to tolerating solid food, whichever occurs later.

Time frame:
Daily for 38 days
Reported as:
Mean · hours

No measurements were reported for this outcome.

SecondaryNasogastric Tube Re-insertion

Proportion of subjects with nasogastric tube re-insertion

Time frame:
Daily for 38 days

Results for this outcome have not been posted.

SecondaryPost-operative Analgesic Use
Time frame:
Daily for 38 days

Results for this outcome have not been posted.

SecondaryAdverse Events

Adverse events grouped by body system

Time frame:
Daily for 38 days

Results for this outcome have not been posted.

SecondaryLaboratory Values

Changes in laboratory values.

Time frame:
Daily for 38 days

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asimadoline 1.0 mg—0/14 (0%)14/14 (100%)
Asimadoline 3.0 mg—1/11 (9.1%)11/11 (100%)
Placebo—1/10 (10%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventAsimadoline 1.0 mgAsimadoline 3.0 mgPlacebo
bleeding gastric ulcerGastrointestinal disorders0/140/111/10
omental necrosisGastrointestinal disorders0/141/110/10
Most frequent other events
Showing 10 of 67
Most frequent other events
EventAsimadoline 1.0 mgAsimadoline 3.0 mgPlacebo
NauseaGastrointestinal disorders5/147/114/10
Procedural PainInjury, poisoning and procedural complications4/145/116/10
Abdominal PainGastrointestinal disorders6/145/113/10
VomitingGastrointestinal disorders1/144/110/10
Abdominal DistensionGastrointestinal disorders4/141/110/10
Incision Site PainInjury, poisoning and procedural complications3/140/111/10
HeadacheNervous system disorders2/142/111/10
Wound InfectionInfections and infestations1/142/111/10
AnaemiaBlood and lymphatic system disorders0/142/110/10
DizzinessNervous system disorders0/142/110/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Asimadoline 1.0 mgAsimadoline 3.0 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years106622
>=65 years45413
Age Continuous
Age Continuous(years)Asimadoline 1.0 mgAsimadoline 3.0 mgPlaceboTotal
Mean58 ± 9.760 ± 12.957 ± 15.358 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Asimadoline 1.0 mgAsimadoline 3.0 mgPlaceboTotal
Female57315
Male94720
Region of Enrollment
Region of Enrollment(participants)Asimadoline 1.0 mgAsimadoline 3.0 mgPlaceboTotal
United States14111035
08

Study locations

4 sites
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
  • Washington University
    St. Louis, Missouri 63110, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106-5047, United States
  • Marks Colorectal Surgical Associates
    Wynnewood, Pennsylvania 19096, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 3 years 11 months after primary completion. A results delay was requested in Aug 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2007
First posted
Mar 5, 2007
Start
Jan 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results delay requested
Aug 23, 2011
Results first posted
Jan 6, 2012
Last update
Jan 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00443040
Lead sponsor
Tioga Pharmaceuticals
Collaborators
RTI Health Solutions
Responsible party
Sponsor
First posted
Mar 5, 2007
Start date
Jan 2007
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Jan 6, 2012
Last update
Jan 6, 2012

Study contacts

Allen Mangel, MD, PhD
study chair · CMO

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asimadoline

Start the discussion